Currently in Beta Testing
AI-powered platform for accurate AML and MDS diagnosis using WHO 2022 and ICC 2022 criteria. Provides risk stratification, treatment guidance, and clinical trial matching for haematologists.
WHO 2022 & ICC 2022 Compliant • Beta Version
Streamline AML and MDS diagnosis with automated classification, risk assessment, and evidence-based treatment recommendations for better patient outcomes.
Process complex pathology reports, genetics, and flow cytometry data to provide accurate AML and MDS classification in minutes, not hours.
ELN 2022 risk assessment for AML and IPSS-M/IPSS-R scoring for MDS, with specialized TP53 risk evaluation and survival predictions.
Evidence-based treatment recommendations, clinical trial matching, and MRD monitoring guidance tailored to patient genetics and risk factors.
Join haematologists and haematopathologists testing our AI-powered AML and MDS classification platform. Help us refine the future of blood cancer diagnosis.